- Home
- FURY vs IMA Comparison
FURY vs IMA Comparison
Compare FURY & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- IMA
- Stock Information
- Founded
- FURY 2008
- IMA 2019
- Country
- FURY Canada
- IMA United States
- Employees
- FURY N/A
- IMA N/A
- Industry
- FURY Precious Metals
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FURY Basic Materials
- IMA Health Care
- Exchange
- FURY Nasdaq
- IMA Nasdaq
- Market Cap
- FURY 84.1M
- IMA 92.2M
- IPO Year
- FURY N/A
- IMA N/A
- Fundamental
- Price
- FURY $0.62
- IMA $8.40
- Analyst Decision
- FURY Strong Buy
- IMA
- Analyst Count
- FURY 2
- IMA 0
- Target Price
- FURY $1.40
- IMA N/A
- AVG Volume (30 Days)
- FURY 592.6K
- IMA 81.6K
- Earning Date
- FURY 11-11-2025
- IMA 11-15-2025
- Dividend Yield
- FURY N/A
- IMA N/A
- EPS Growth
- FURY N/A
- IMA N/A
- EPS
- FURY N/A
- IMA N/A
- Revenue
- FURY N/A
- IMA $4,300,000.00
- Revenue This Year
- FURY N/A
- IMA N/A
- Revenue Next Year
- FURY N/A
- IMA N/A
- P/E Ratio
- FURY N/A
- IMA N/A
- Revenue Growth
- FURY N/A
- IMA N/A
- 52 Week Low
- FURY $0.35
- IMA $7.57
- 52 Week High
- FURY $0.73
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- FURY 48.51
- IMA N/A
- Support Level
- FURY $0.61
- IMA N/A
- Resistance Level
- FURY $0.68
- IMA N/A
- Average True Range (ATR)
- FURY 0.04
- IMA 0.00
- MACD
- FURY -0.01
- IMA 0.00
- Stochastic Oscillator
- FURY 13.28
- IMA 0.00
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.